Adenovirus expressing melanoma-associated antigen A3: Phase I/IIa started

Turnstone began an open-label, dose-escalation, Canadian Phase I/IIa trial to compare adenovirus expressing MAGEA3/MG1 Maraba virus expressing MAGEA3 vs. the product’s 2 components separately in up to...